- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.08. | Facing pressure from Novartis, Eli Lilly trots out Verzenio patient survival win in early breast cancer | ||
| 27.08. | Amylyx axes rare disease program after Relyvrio fails to beat placebo | ||
| 27.08. | Massachusetts' biopharma hotbed shed R&D, manufacturing workers in '24 as new threats now come to the fore | ||
| 27.08. | C is for check-up: Phreesia brings Sesame Street to patient intake platform | ||
| 26.08. | Akeso, Summit's PD-1xVEGF drug meets overall survival goal for the first time in a lung cancer trial | ||
| 26.08. | Sanofi snags BioMarin leader to take on CMO role 8 months after Berger's exit | ||
| 26.08. | Pfizer lays off 100 workers at former Seagen HQ in Seattle area | ||
| 26.08. | Bayer plugs $43M into Veracruz API site amid sweeping expansion drive in Mexico | ||
| 26.08. | Nusano debuts radioisotope production plant in Salt Lake City amid industry's supply squeeze | ||
| 25.08. | With late-stage trial win, Argenx preps FDA filing to push Vyvgart into broader myasthenia gravis population | ||
| 25.08. | MannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M deal | ||
| 25.08. | FDA does a 180, suspending use of Valneva's chikungunya vaccine | ||
| 25.08. | FDA rolls out daily updates to adverse event dashboard, plans to further 'streamline' system | ||
| 25.08. | BeOne bags $885M upfront in Royalty deal on Amgen's lung cancer drug Imdelltra | ||
| 22.08. | Bavarian Nordic CEO says buyout needed for vaccine specialist to reach its potential | ||
| 22.08. | UK pharma drug price talks break down as industry fails to lower discount rate | ||
| 22.08. | Novo plant acquired in Catalent buyout faces renewed FDA scrutiny with Form 483: STAT | ||
| 22.08. | Serena Williams gets in the Ro boat, discussing her GLP-1 use as a celebrity ambassador | ||
| 22.08. | Big Pharma bounces back in Q2 | ||
| 21.08. | Ionis steps into crowded HAE market with FDA approval for Dawnzera | ||
| 21.08. | For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo | ||
| 21.08. | AbbVie corporate campaign celebrates the patients, scientists behind its medicines | ||
| 21.08. | AbbVie strengthens Rinvoq's case to treat alopecia, will send data to regulators | ||
| 21.08. | Sarepta extends $700M debt to 2030, adds private placement amid Elevidys uncertainty | ||
| 21.08. | Trump locks in 15% tariff rate for EU, confirming separate 'Most Favored Nation' duty for generic drugs |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .